| PROSPECTUS SUPPLEMENT | Filed Pursuant to Rule 424(b)(3) |
(To Prospectus Supplement dated May 26, 2023 and Prospectus dated July 30, 2021) | Registration No. 333-258145 |
Fortress Biotech, Inc.
Up to $11,958,791
Common Stock
This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in our prospectus dated July 30, 2021 (the “Base Prospectus”), as supplemented by our prospectus supplement dated May 26, 2023 (the “Initial Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”), filed pursuant to our registration statement on Form S-3 (File No. 333-258145) (the “Registration Statement”), covering the offering, issuance and sale by us of our common stock that may be issued and sold under the At Market Issuance Sales Agreement entered into with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), H.C. Wainwright & Co., LLC and Dawson James Securities, Inc. (each, an “Agent” and together, the “Agents”), dated May 29, 2020 (the “Sales Agreement”). This Prospectus Supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.
In accordance with the terms of the Sales Agreement, under this Prospectus Supplement and accompanying Prospectus we may offer and sell shares of our common stock, $0.001 par value per share, from time to time through the Agents, acting as agent.
We are filing this Prospectus Supplement to amend the Prospectus to update the amount of common stock we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. On March 28, 2024, the date we filed our Annual Report on Form 10-K for the year ended December 31, 2023, our Registration Statement became subject to the offering limits set forth in General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $11,958,791 from time to time through or to the Agents. In the event that we become eligible to sell additional amounts under the Sales Agreement in accordance with General Instruction I.B.6 or otherwise, we will file another prospectus supplement prior to making such additional sales.
Our common stock is listed on the Nasdaq Capital Market under the symbol “FBIO”. As of April 5, 2024, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was $36,292,419, which was calculated based on 14,971,114 shares of our common stock outstanding held by non-affiliates as of April 4, 2024 at a price of $2.43 per share, the last reported sale price for our common stock on March 1, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event may we offer securities pursuant to this Prospectus Supplement with an aggregate offering price of more than one-third of our public float or approximately $12,126,602, in any 12-calendar month period for as long as our public float is less than $75,000,000. As of the date hereof, we have offered and sold $167,811 of common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date hereof.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-3 of the Initial Prospectus Supplement and the risks and uncertainties described in the documents we file with the Securities and Exchange Commission that are incorporated in this Prospectus Supplement and the Prospectus by reference for certain risks and uncertainties relating to an investment in our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus Supplement and the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| B. Riley Securities | H.C. Wainwright & Co. | Dawson James |
The date of this Prospectus Supplement is April 5, 2024.